WXXWY (WuXi Biologics (Cayman)) FCF Margin % : -6.59% (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. WuXi Biologics (Cayman)'s Free Cash Flow for the six months ended in Jun. 2024 was $-78 Mil. WuXi Biologics (Cayman)'s Revenue for the six months ended in Jun. 2024 was $1,182 Mil. Therefore, WuXi Biologics (Cayman)'s FCF Margin % for the quarter that ended in Jun. 2024 was -6.59%.

As of today, WuXi Biologics (Cayman)'s current FCF Yield % is -0.47%.

The historical rank and industry rank for WuXi Biologics (Cayman)'s FCF Margin % or its related term are showing as below:

WXXWY' s FCF Margin % Range Over the Past 10 Years
Min: -73.83 Med: -32.57 Max: 2.57
Current: -1.85

During the past 10 years, the highest FCF Margin % of WuXi Biologics (Cayman) was 2.57%. The lowest was -73.83%. And the median was -32.57%.

WXXWY's FCF Margin % is ranked better than
76.94% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs WXXWY: -1.85

WuXi Biologics (Cayman) FCF Margin % Historical Data

The historical data trend for WuXi Biologics (Cayman)'s FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) FCF Margin % Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-50.87

-73.83

-30.05

-2.14

2.57

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial														-17.02	11.16	2.30	2.83	-6.59

Competitive Comparison of WuXi Biologics (Cayman)'s FCF Margin %

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s FCF Margin % distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s FCF Margin % falls into.

WuXi Biologics (Cayman) FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

WuXi Biologics (Cayman)'s FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	61.231	/	2385.683
	=	2.57 %

WuXi Biologics (Cayman)'s FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-77.917	/	1181.884
	=	-6.59 %

WuXi Biologics (Cayman) FCF Margin % Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

WXIBF:USA 02269:Hong Kong 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.